Vir Biotechnology Announces First Patient Dosed in Groundbreaking Phase 2 Trial of VIR-2482 for Antibody Prophylaxis of Influenza A
18 oct. 2022 08h00 HE
|
Vir Biotechnology, Inc.
– First clinical trial evaluating the role of a monoclonal antibody in preventing seasonal flu – – Announcement follows recent U.S. government award from the Biomedical Advanced Research and...
Vir Biotechnology to Participate in the H. C. Wainwright 3rd Annual Hepatitis B Virus (HBV) Conference
11 oct. 2022 16h03 HE
|
Vir Biotechnology, Inc.
SAN FRANCISCO, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Ph.D., executive vice president, chief medical officer and interim head...
Vir Biotechnology Awarded U.S. Government Contract to Support Pandemic Preparedness for Influenza and Other Infectious Disease Threats
04 oct. 2022 08h00 HE
|
Vir Biotechnology, Inc.
– First award from the agency’s solicitation for contracts for Pre-Exposure Prophylaxis for Influenza – – Initial investment of approximately $55 million from Biomedical Advanced Research and...
Vir Biotechnology Announces First Patient Dosed in the Phase 2 SOLSTICE Trial Evaluating VIR-2218 and VIR-3434 for the Treatment of Chronic Hepatitis D Virus Infection
22 sept. 2022 08h00 HE
|
Vir Biotechnology, Inc.
– Impacting more than 12 million people globally, HDV is the most aggressive form of viral hepatitis – – Novel combination strategy designed toreduce HDV viremia and block viral entry – SAN...
Moore Kuehn, PLLC Encourages Investors of Vir Biotechnology, Inc. to Contact Law Firm
31 août 2022 09h55 HE
|
Moore Kuehn
NEW YORK, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Vir Biotechnology, Inc....
Vir Biotechnology Appoints Johanna Friedl-Naderer as Executive Vice President and Chief Business Officer, Global
08 févr. 2022 06h00 HE
|
Vir Biotechnology, Inc.
SAN FRANCISCO, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Johanna Friedl-Naderer as Executive Vice President and Chief...
Vir Biotechnology to Present at 40th Annual J.P. Morgan Healthcare Conference
04 janv. 2022 16h02 HE
|
Vir Biotechnology, Inc.
SAN FRANCISCO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that George Scangos, Ph.D., chief executive officer, will present at the 40th Annual J.P....
Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2021 Financial Results on August 5, 2021
22 juil. 2021 16h05 HE
|
Vir Biotechnology, Inc.
SAN FRANCISCO, July 22, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the second quarter...
Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Oral and Poster Presentations at EASL 2021
14 juin 2021 08h00 HE
|
Vir Biotechnology, Inc.
SAN FRANCISCO, June 14, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that four abstracts highlighting data from its hepatitis B clinical program have been accepted...
Vir Biotechnology to Participate in the Goldman Sachs 42nd Annual Global Healthcare Conference
02 juin 2021 16h05 HE
|
Vir Biotechnology, Inc.
SAN FRANCISCO, June 02, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that George Scangos, Ph.D., chief executive officer, will participate in a virtual fireside...